Htra1 Cerebral Small Vessel Disease Htra1 Csvd Cn381340
HTRA1 cerebral small vessel disease is a genetic condition affecting small brain blood vessels, increasing stroke risk. It can cause progressive neurological symptoms and vascular dementia. Management includes stroke prevention and symptom control.
Key facts at a glance
- ICD-10
- G40.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Ischemic stroke
Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Cognitive decline
(neurologic)Gait disturbance
(neurologic)Visual field defects
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Antihypertensive therapy
Rigorous blood pressure control to slow disease progression and reduce stroke risk. ACE inhibitors or ARBs are often preferred due to potential renoprotective effects in small vessel disease.
Drug therapy and clinical monitoring
Active treatment with regular monitoring by a healthcare provider is recommended.
Cardiovascular risk reduction program
Comprehensive lifestyle modification including smoking cessation, regular aerobic exercise, weight management, and stress reduction to address modifiable vascular risk factors.
Additional treatment options
Antiplatelet therapy
Consideration of antiplatelet agents for secondary stroke prevention in appropriate patients. Risk-benefit assessment required given potential bleeding risk in cerebral small vessel disease.
medicationCognitive and neurological surveillance
Regular neuropsychological assessment and neurological examination to monitor for cognitive decline, gait disturbances, and early signs of stroke or vascular events requiring intervention.
monitoringCognitive rehabilitation services
Targeted cognitive training and rehabilitation to maintain executive function, processing speed, and memory. May include computer-based training programs and compensatory strategy teaching.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Htra1 Cerebral Small Vessel Disease Htra1 Csvd Cn381340?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Htra1 Cerebral Small Vessel Disease Htra1 Csvd Cn381340. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy